×
Abstract GS1-01: Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and ...
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS1-01

Feb 16th, 2018 - Background: Much contemporary adjuvant chemotherapy uses conventional 3-weekly scheduling. Yet, cytokinetic modelling suggests that increasing the dose density of cytotoxic therapy by shortening the intervals between courses, or by using sequential rather than concurrent treatment schedules may enhance efficacy.1 At least 15 randomised trials have directly tested this hypothesis and this meta-a...

Abstract P1-15-04: Outcome of small (≤1 cm), node-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-15-04

Sep 20th, 2018 - Background: Screening mammogram has resulted in increased diagnosis of very small breast cancers, especially less than 1 cm node negative. These small tumors have excellent prognosis with cancer-specific survival rates as high as 90% to 95%. This study evaluates outcome in different subtypes of very early breast cancer in a national population database. Method: Patients with stage I breast canc...

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C ...
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS1-02

Feb 19th, 2018 - Background: Adjuvant trastuzumab (H) reduces cancer recurrence and improves survival in patients (pts) with HER2-amplified or overexpressing (IHC 3+ staining intensity) IBC. Two of the landmark trials that demonstrated the efficacy of H-based eligibility on HER2 testing performed at local site laboratories were found to contain a cohort of pts without amplification or IHC overexpression on tiss...

Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-15-01

Sep 21st, 2018 - BACKGROUND: The SWOG S0230/POEMS study demonstrated a 70% reduction in ovarian failure (OF) with goserelin coadministration during chemotherapy (CT) for ER-negative early breast cancer (BC; Moore H et al, NEJM 2015). Goserelin use was also associated with more pregnancies as well as favorable disease free survival (DFS) and overall survival (OS). Here we report the final analysis after 5 years ...

Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or ...
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS2-07

Feb 24th, 2018 - Background: Resistance to endocrine therapy remains a major clinical challenge with aberrant PI3K/ mTOR pathway activation being one of the main drivers. Randomised clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Vistusertib (AZD2014), a dual inhibitor of mTORC1 and mTORC2, has shown a broader range of activity in preclinical ER+ breast cancer ...

Abstract P5-22-13: Representation of surgical breast research at an interdisciplinary oncology conference
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-13

Dec 25th, 2018 - Background: The treatment of breast cancer requires an interdisciplinary approach, involving the fields of surgery, radiation oncology, medical oncology, pathology and radiology. The roles of various specialties may differ in the local versus metastatic setting. Despite the importance of collaborative care, significant disparities remain in federal funding of research among different medical sp...

Abstract GS5-01: Appropriate margins for breast conserving surgery in patients with early stage breast cancer: A meta-analysis
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS5-01

Feb 27th, 2018 - Background: Significant controversy exists regarding the appropriate minimum tumor-free margin width for patients undergoing breast-conserving therapy. The SSO-ASTRO guidelines recommend 'no ink on tumor' based upon a meta-analysis of 33 studies, but this had significant limitations. In order to address these concerns, a meta-analysis of all available data (using 31 of the initial studies) was ...

Abstract P5-22-21: Radioactive seed and targeted axillary dissection: A feasibility study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-21

Dec 26th, 2018 - Targeted axillary dissection (TAD) with a radioactive seed is a new and promising technique to evaluate the axillary status in post-neoadjuvant chemotherapy (NACT) node-positive breast cancer patients. This study aims to evaluate the feasibility of TAD with a radioactive seed in a Canadian setting. We conducted a retrospective observational study of a prospectively gathered database of patients...

Abstract GS4-06: Cancer risks and response to targeted therapy associated with BRCA2 variants of uncertain significance
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS4-06

Mar 4th, 2018 - Background: Germline genetic testing of individuals with a diagnosis of triple negative breast cancer, young age at diagnosis, or a family history of breast and/or ovarian cancer has led to the identification of many unique BRCA2 missense variants of uncertain significance (VUS). VUS in BRCA2 are predominantly missense mutations that have unclear relevance to breast, ovarian, and other cancers....

Abstract P1-15-05: Oncologists' perception of anti-estrogen therapy benefit
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-15-05

Sep 25th, 2018 - Background Recent publication of Suppression of Ovarian Function (SOFT) and Tamoxifen and Exemestane (TEXT) trials provides additional options for premenopausal women with hormone receptor (HR)-positive breast cancer in improving estrogen blockade - tamoxifen (T) plus ovarian function suppression (OFS) and aromatase inhibitors (AI) plus OFS. Analysis of these trials conclude that, for a premeno...

Abstract P1-15-06: Localized triple negative breast cancer in extremes of life
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-15-06

Sep 26th, 2018 - Background: Triple-negative breast cancer (TNBC) in young and older patients has specific features and outcomes. While in younger patients, it is characterized by being aggressive with worse survival, in advanced ages it may have a better outcome which reasons have not yet fully elucidated. Our objective was to compare clinicopathological characteristics, treatment and survival rates between ve...

Abstract GS5-07: Weight change in postmenopausal women and breast cancer risk in the women's health initiative observational study
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS5-07

Mar 16th, 2018 - Purpose While obesity is an established breast cancer risk factor, information about the influence of weight loss on breast cancer risk in postmenopausal women is mixed precluding generation of a strong public health message regarding potential benefits of weight loss with respect to cancer risk. Therefore, we evaluated associations between weight change and invasive breast cancer risk in postm...

Abstract P1-14-06: Selective internal radiation therapy (SIRT) with Yttrium-90 resin microspheres and FOLFOX/5FU chemotherapy in pre-treated breast cancer patients with liver metastases: A retrospe...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-14-06

Sep 27th, 2018 - Background: SIRT is a globally licensed technique of Radio-Embolization (RE) of hepatic tumors via intra-arterial infusion of β-particle emitting Yttrium-90 (Y-90) radio-labelled microspheres. It increases response rates and hepatic time to progression in metastatic colorectal cancer when used in combination with 5FU/Oxaliplatin (FOLFOX) chemotherapy with acceptable toxicity profile. FOLFOX giv...

Abstract BS2-1: Ocogenic and microenvironmental signals driving early dissemination, dormancy and metastasis
http://cancerres.aacrjournals.org/content/78/4_Supplement/BS2-1

Mar 24th, 2018 - The mechanisms that produce early-disseminated cancer cells (eDCC) during early stages of breast cancer or that contribute to the development of metastasis from cancer of unknown primary (CUP) are poorly understood. Here we show that HER2+ cancer cells that are present during early stages of cancer before any overt tumors can be detected are highly efficient in systemically disseminating from p...

Abstract ES9-2: Tracking progesterone receptor actions in breast cancer progression: Jekyll and Hyde
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES9-2

Apr 1st, 2018 - Recent work on the actions for progesterone receptors (PRs) in breast cancer has raised the profile of PRs as players rather than simply markers of estrogen (E)-responsive luminal disease. Indeed, estrogen receptors (ERs) and PRs are intimate partners at the genome regulatory level rather than having a simple driver/passenger relationship. PRs alter breast cancer cell proliferation in complex w...

Abstract ES11-1: Luminal ABC: optimal use of all available options?
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES11-1

Apr 5th, 2018 - Despite advanced in early detection and aggressive adjuvant endocrine therapy, recurrence and metastasis of estrogen-receptor (ER)- positive breast cancer remains a problem, with a substantial proportion of patients relapsing years after diagnosis. Biologically, these tumors are primarily of the luminal subtype, amenable to anti-estrogen strategies that can control disease growth and limit meta...

Abstract ES2-1: The pathology of high risk proliferative lesions of the breast
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES2-1

Apr 9th, 2018 - A number of breast lesions diagnosed by pathologic examination of breast tissue are known to confer an increased risk for future development of breast cancer. Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) are lesions conferring a moderately increased risk of 4-5x over baseline. Lobular carcinoma in situ (LCIS) and variants confer a markedly increased risk of 8-10x ove...

Abstract P1-11-01: Effectiveness, safety and quality of life (QoL) results from the German multicenter AVANTI study of 1st-line bevacizumab (BEV)-containing therapy in >2000 patients (pts) with ...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-11-01

Oct 3rd, 2018 - Background: In Europe, BEV is approved with either paclitaxel (PAC) or capecitabine (CAP) as 1st-line therapy for HER2-negative aBC. These regimens are being evaluated in routine oncology practice in the German AVANTI (ML22452) observational study. Methods: Eligible pts had received no prior chemotherapy (CT) for aBC and had no BEV contraindications. CT schedule, diagnostics and frequency of fo...

Abstract P1-12-02: Clinical efficacy of a humanized monoclonal antibody against the Lewis-Y antigen (Ley): Results of a phase II clinical trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-12-02

Oct 4th, 2018 - Background. The Lewis-Y (Ley) antigen is a blood group-related antigen expressed in over 70% of epithelial cancers. It is expressed in 44% of breast cancers. Objectives. The primary endpoint was to evaluate the clinical efficacy of hu3S193, a humanized monoclonal antibody against the Lewis-Y antigen, in advanced hormone positive breast cancer after failure of at least one line of endocrine ther...

Abstract P2-01-03: Improved prognostic information by serial monitoring of CTC enumeration and CTC-clusters from baseline to six months in patients with metastatic breast cancer scheduled for 1st l...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-01-03

May 7th, 2018 - Background: Detection and enumeration of circulating tumor cells (CTCs) allows real time monitoring of disease evolvement. In women with metastatic breast cancer (MBC), a CTC count of ≥5 CTCs is associated with decreased progression-free survival (PFS) and overall survival (OS). Serial sampling after therapy initiation has indicated that longitudinal CTC enumeration adds prognostic information,...

Abstract P1-17-07: Preclinical characterization of neratinib in a blood-brain barrier co-culture model: Therapeutic implications for breast cancers with brain metastases
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-07

Oct 9th, 2018 - Background: Breast cancer patients who develop brain metastases have poor prognosis/short overall survival. Human epidermal growth factor receptor 2 (HER2) +ive breast cancer have an increased propensity for brain metastases. Currently, these metastases have limited therapeutic options. The endothelial cells forming the blood-brain barrier (BBB) are highly specialized to allow precise control o...

Abstract P5-09-03: Intrinsic heterogeneity of triple-negative breast cancer cells triggers vascular mimicry in 3D matrigel matrix environment
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-09-03

Jan 10th, 2019 - Within the same tumor microenvironment phenotypic and functional heterogeneity arise among cancer cells as a consequence of genetic change, environmental differences, and reversible epigenetic changes in cellular properties. However, it is thought that cancer stem cells are drivers of drug resistance and metastasis. Individual tumor cells growing in culture also display heterogeneity in their i...

Abstract P5-01-02: Quantitative assessment of tumor response to neoadjuvant chemotherapy in women with locoregional invasive breast cancer using Tc99m sestamibi molecular breast imaging - prelimina...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-01-02

May 15th, 2018 - Purpose: To report preliminary data in a pilot study evaluating the ability of Tc99m sestamibi Molecular Breast Imaging (MBI) to predict response and assess residual disease at the completion of neoadjuvant chemotherapy (NAC) in breast cancer patients. Materials and Methods: Patients with localized, invasive breast cancer (T1-T4, N0-N3, M0) planned for NAC were enrolled in this prospective IRB ...

Abstract P2-01-05: Comprehensive analysis of genomic alterations in tumor tissue associated with presence of various subpopulations of circulating tumor cells (CTCs) in primary breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-01-05

May 14th, 2018 - Background: CTCs play a major role in tumor dissemination and progression, and represent one of the key components of the metastatic cascade. The aim of this study was to identify signaling pathways associated with presence of CTCs in primary breast cancer (PBC) patients using a comprehensive genomics approach. Methods: This translational study included 78 patients with PBC. CTCs were detected ...

Abstract P5-10-01: Cellular senescence within HER2-amplified breast cancer: Potential implications for breast cancer immune surveillance and HER2-targeted therapy resistance
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-10-01

Jan 11th, 2019 - Background:Oncogene-induced senescence is considered as a barrier to tumor progression that arrests cells at risk for malignant transformation. Nevertheless, numerous findings demonstrate that senescent cells may also have the opposite function and promote tumor progression through the release of multiple factors called the senescence-associated secretory phenotype or senescence secretome. It i...

Abstract P6-03-11: Differences in serum miRNA signatures in women with pathology-confirmed breast cancer, benign breast diseases and healthy individuals with no cancer history
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-03-11

May 18th, 2018 - [INTRODUCTION] Mammography is the principal non-invasive imaging method of screening for breast cancer around the world. Mammography has been shown to be effective in reducing breast cancer deaths in randomized studies (Tabar et al., 2011 and Duffy et al., 2002). However, screening mammography can result in false positives that require subsequent interventions such as biopsy or interval repeat ...

Abstract P5-10-02: High expression of BAD, PUMA, BOK and TRADD mRNA is associated with higher overall survival in ER+ and PR+ breast cancer patients
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-10-02

Jan 12th, 2019 - Background: Apoptosis signalling is controlled by a complex interaction of pro- and anti-apoptotic BCL2 proteins and its dysregulation is believed to be a major contributor to therapy responses and resistance in cancer. We previously demonstrated that inhibition of cell death in cancer cell is associated to poor outcome in colorectal cancer (Lindner et al., Cancer Res, 2012) and to lower cell d...

Abstract P6-03-07: An automated DNA methylation assay (QM-MSP) for rapid breast cancer diagnosis in underdeveloped countries
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-03-07

May 26th, 2018 - BACKGROUND: Underdeveloped countries reported 882,900 new cases of breast cancer and 324,000 deaths in 2012, likely to be a gross underestimation according to recent reports. Often, mammography screening is not available, primary care services are limited, and pathology and treatment services are available only in the regional hospitals. Because of the lack of access to diagnostic and treatment...

Abstract P1-17-04: Clinical presentation and outcome of leptomeningeal metastasis in patients with breast cancer in relation to histology and tumor subtypes
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-04

Oct 14th, 2018 - Background: Among solid tumors, breast cancer (BC) is one of the most common cause of leptomeningeal metastases. Leptomeningeal disease (LMD) typically carries a devastating prognosis; however, disease presentation and prognostic factors are still uncertain. The aim of this study was to characterize clinical features of LMD in relation to BC histology and subtypes. Patients and Methods:104 pati...

Abstract P6-02-01: Perceived life expectancy, multimorbidity, and breast cancer screening in older women
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-02-01

May 30th, 2018 - Objective: Screening mammography (SM) benefits are maximal in women who have a several years' life expectancy. Perceived life expectancy (PLE), however, can be compromised by older age, and/or poor health. Prior studies have shown low rates of SM in younger and/or healthier women, while women who are older and/or those presenting with multimorbidity (MM) continue to undergo screening. The resul...

Abstract P3-17-02: Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-17-02

Oct 15th, 2018 - Background: Progression free-survival (PFS) is the dominant endpoint in phase 3 randomized controlled trials (RCTs) in women with metastatic breast cancer (MBC), and requires the ability to measure target lesions. It is unknown whether treatment effect on PFS is consistent among patients with measurable and non-measurable disease. Methods: We searched MEDLINE, EMBASE and COCHRANE for phase 3 RC...

Abstract P6-10-04: “Disparities in breast cancer: A multi-institutional comparative analysis focusing on American Hispanics”
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-10-04

May 31st, 2018 - Background: Breast cancer (BC) is the leading cause of cancer death in Hispanic/Latina women nationwide. Hispanic women are more likely to be presented with advanced disease and might have adverse prognosis. Further, the Hispanics of Mexican-American origin might reflect different clinico-pathological characteristics as opposed to other Hispanics and ethnic groups. No previous largest studies c...

Abstract P3-17-03: Concordance of real world progression free survival (PFS) on endocrine therapy as first line treatment for metastatic breast cancer using electronic health record with proper qua...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-17-03

Oct 16th, 2018 - Background: There is growing interest to assess treatment effect with clinical endpoints that are reflective of real world clinical practice based on data systemically collected from the electronic health record (EHR). This study compared real world PFS (rwPFS) among a cohort of female patients (pts) treated with letrozole (LET) monotherapy as first-line therapy for metastatic breast cancer (MB...

Abstract P6-10-07: Differences in genome-wide DNA methylation levels in breast milk by race and lactation duration
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-10-07

Jun 7th, 2018 - Introduction: Identifying biomarkers of breast cancer risk among young women would have value in developing effective screening and prevention strategies at early ages. We have proposed that DNA methylation analysis of breast milk may provide breast cancer risk information among young women, and could possibly provide etiologic clues related to the higher rates of early onset cancers among Afri...

Abstract P6-05-03: Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-05-03

Jan 16th, 2019 - Most BRCA1-associated breast tumours are basal-like yet originate from luminal progenitors. BRCA1 is best known for its functions in double-strand break repair and resolution of DNA replication stress. However, it is unclear whether loss of these ubiquitously important functions fully explains the cell lineage-specific tumorigenesis. In vitro studies implicate BRCA1 in elimination of R-loops, D...

Abstract P4-06-18: Clinical application of multigene panel testing and genetic counseling for hereditary/familial breast cancer risk assessment: Prospective single center study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-06-18

Jun 8th, 2018 - Background The identification of individuals at elevated risk for hereditary cancers has allowed the development of consensus recommendations for cancer screening and prevention. The introduction of multigene panels may identify more individuals with breast cancer gene mutations than does testing for BRCA1/2 alone. Therefore, the multigenerational panel increase the need for genetic counseling ...

Abstract P6-05-02: Targeting vesicular trafficking machinery for breast cancer therapeutics
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-05-02

Jan 17th, 2019 - The Rab GTPase family is a key regulator of vesicular import, transport and export. Deregulation of vesicular trafficking promotes undesirable intercellular cross talk via exosomes that contribute to cancer pathophysiology. Preclinical and clinical studies underscore a role for exosomes and their cargo in breast cancer development, progression, metastasis, and resistance to therapy. While many ...

Abstract P4-06-06: Frequency of mutations in multi-gene panel testing of 3,011 breast cancer patients
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-06-06

Jun 15th, 2018 - Objectives: Here, we describe the characteristics of 3,011 individuals with a self-reported diagnosis of breast cancer who received a multi-gene panel genetic test for hereditary cancer risk. Methods: These 3,011 patients were referred physician order for a multi-gene, next generation sequencing panel for hereditary cancer risk. Analysis was limited to 19 genes associated with hereditary breast...

Abstract P1-08-02: Breast tumor-specific MHC-II expression drives a unique pattern of adaptive resistance to antitumor immunity through MHC-II receptor checkpoint engagement
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-08-02

Oct 19th, 2018 - Background: We have previously shown that some breast cancers express major histocompatibility complex II (MHC-II), correlating with enhanced immune infiltration. In other tumor types, we have shown that MHC-II expression on tumor cells predicts clinical response to checkpoint inhibition. We sought to determine the direct effects of MHC-II on anti-tumor immunity and characterize mechanisms of i...

Abstract P5-23-05: Prognostic value of PD-L1 expression in male breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-23-05

Oct 23rd, 2018 - Background Growing evidence have shown promise for targeting programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling in several tumors. In female breast cancer, PD-L1 expression has been correlated with poor clinical outcome. However, whether PD-L1 has any indication for prognosis in male breast cancer (MBC) patients remains unknown. The purpose of this study was to examine the ex...

Abstract P2-10-04: Targeted sequencing in early breast cancer: Identification of novel candidate mutations predictive of anthracycline benefit
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-10-04

Jul 2nd, 2018 - Background The use of chemotherapies such as anthracyclines and taxanes have improved overall and disease free survival in breast cancer. For all patients, anthracyclines can have significant toxicities including cardiotoxicity and leukemia. It is therefore essential to select the subset of patients who will receive the optimal overall benefit from anthracycline therapy and to identify molecula...

Abstract P5-23-04: Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-23-04

Oct 24th, 2018 - Background: Seviteronel (Sevi), an oral selective CYP17-lyase and AR inhibitor that blocks testosterone and estradiol production whilst competitively antagonizing the AR, is in Ph 2 clinical development for the treatment of advanced prostate and breast cancers (BC). Male BC is a high unmet need. Men with BC have a high rate of advanced disease at the time of diagnosis and disease-related deaths...

Abstract P2-10-07: A prospective clinical utility study of the impact of the 21-gene recurrence score (RS) assay in the treatment of estrogen receptor positive (ER+), HER2 negative (HER2-), 1-3 nod...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-10-07

Jul 9th, 2018 - Background: The 21-gene RS is routinely used in node negative ER+, HER2- BC to help guide chemotherapy treatment decision making. There is emerging use of the RS in limited N+ BC, though the results from the randomized clinical trial (RxPONDER) is pending. The objective of the study is to determine whether the results of the 21-gene RS will alter physician treatment decisions in ER+ HER2- limit...

Abstract P5-23-01: Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registry
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-23-01

Oct 25th, 2018 - BACKGROUND: Through the International Male Breast Cancer Program, a prospective registry for male BC was created with the goals of evaluating 1) the clinical and biological features of this disease and 2) assessing feasibility of a prospective therapeutic clinical trial. METHODS: All men, with any stage histologically proven invasive breast cancer, age 3 18 years, and newly presenting at the pa...

Abstract P4-09-07: Validation of 12-gene chemokine signature as a predictor of treatment response in breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-09-07

Jul 13th, 2018 - Background: We had previously derived a unique 12-chemokine gene expression score (CS) from a metagene grouping with high enrichment for immune-and inflammation-related genes. A review of selected Stage I - III breast cancer patients showed that higher CS were associated with high-grade tumors and aggressive subtypes and in the HER2 positive group, correlated with increased recurrence free surv...

Abstract P4-09-02: Disseminated tumor cells as predictive factor of benefit of lymph node irradiation to prevent loco-regional relapse
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-09-02

Jul 10th, 2018 - Background: Early stage breast cancer patients with micrometastatic spread (cM0(i+) per the 2010 TNM staging), detected either in the bone marrow (disseminated tumor cells, DTC) or in the blood (circulating tumor cells, CTC) are at higher risk of distant relapse and death. Loco-regional relapses were also more frequently observed in patients with DTC and, recently, with CTC (IMENEO study, Bidar...

Abstract P5-23-06: Metastatic pattern in stage IV male breast cancer at initial diagnosis: A population-based study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-23-06

Oct 27th, 2018 - Background: Male breast cancer (MaBC) is a relatively uncommon disease, representing less than 1% of all breast cancers. Although men tend to present at more advanced stages, the prognostic influence of metastatic pattern (MP), sites of metastases and factors associated with specific organ involvement are unknown. The primary aim of this study was to analyze the influence of MP compared with ot...

Abstract P5-11-01: The accuracy of nomograms based on large dataset using clinico-pathologic variables for prediction of oncotype DX breast cancer recurrence score
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-11-01

Jul 18th, 2018 - Purpose The 21 gene expression assay, Oncotype DX (ODX) is costly (the current estimated cost is ˜$4000), and were tested in only approximately one-third of breast cancer patients who meet the inclusion criteria in the United States. Recent study of University of Tennessee Medical Center reported a novel nomogram for prediction of ODX recurrence score using clinico-pathologic data, which was ba...

Abstract P4-08-07: PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-posit...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-08-07

Jul 25th, 2018 - Background: Endocrine therapy is the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. We recently reported that approximately two-thirds of patients who relapsed within 5 years had received anthracyclins and/or taxanes as adjuvant or neoadjuvant chemotherapy in addition to adjuvant endocrine therapy. New strategies, such as signal transduction inhibi...

Abstract P4-03-04: Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-03-04

Jan 27th, 2019 - Background: Despite the advent of HER2-targeted therapies for HER2+ breast cancer (BC), including the monoclonal antibody trastuzumab (T) either alone or in combinations, resistance still poses a major clinical challenge. Using our broad panel of HER2+ cell lines made resistant (R) to T alone (TR), and to lapatinib plus T (LTR), we observed that in resistant models where HER2 remains inhibited,...